Coronavirus Update: Gilead Says 'Inappropriate Characterizations' In Remdesivir Trial Flop Leak
Plus: J&J Finds Manufacturing Partner, AZ To Investigate Heart Complications
The leaked abstract suggests remdesivir provides no benefits for patients - but analysts say conclusions are hard to draw from underpowered trial.
You may also be interested in...
Results from the first major trial of remdesivir are positive, but fail to show clear mortality benefit - making its forthcoming approval just the first step towards winning the war on COVID-19.
Analysts see NIAID’s placebo-controlled data as more important than Gilead’s open-label data. Quick emergency use authorization by FDA is possible, but the US agency has not confirmed EUA.
AstraZeneca, during a strong first-quarter update, underscored its determination to test existing portfolio assets for use in fighting the COVID-19 pandemic.